Introduction and Background
Since the pioneering work of Alexander Fleming, Paul Ehrlich, Gerhard Domagk, and others on antibiotics about 100 years ago,t he benefits of these "miracle drugs" for the treatment of infectious diseases have been taken for granted in public health. Unfortunately,adramatic change has taken place in recent years in terms of the efficacyofadministered antibiotics.M ore and more bacteria have developed resistance against antibiotics,a nd these resistant microorganisms can withstand attack by antimicrobial drugs so that standard treatments become ineffective and infections persist, thereby increasing the risk of spreading to others. [1] Theevolution of resistant strains is anatural phenomenon that occurs through selection pressure on the microorganism population from the antibiotic.T here are currently five main targets for antibiotics,and antibiotic resistance can essentially be acquired through four different pathways and expressed by four different mechanisms ( Figure 1 ).
Theuse and misuse of antimicrobial drugs accelerates the emergence of drug-resistant strains.A ccording to the World Health Organization (WHO), there were about 480 000 new cases of multidrug-resistant tuberculosis (MDR-TB) in 2013 and extensively drug-resistant tuberculosis (XDR-TB) has been identified in 100 countries. [1] There are high proportions of antibiotic resistance in bacteria that cause common infections (e.g.,u rinary tract infections,p neumonia, bloodstream infections) in all regions of the world. As ubstantial percentage of hospital-acquired infections are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), or multidrug-resistant Gram-negative bacteria that are resistant to all b-lactam antibiotics.
Patients with infections caused by drug-resistant bacteria are generally at increased risk of worse clinical outcomes and death, and they consume more health-care resources than patients infected with the same bacteria that are not resistant. [1] Owing to the discovery gap during the last decades for novel antibiotic chemotherapies in the pharmaceutical industry and to the occurrence of bacterial strains resistant to the current antibiotics,p ublic health is running out of treatment options for dealing with infectious diseases.I no rder to respond to this emerging crisis,g lobal organizations such as the WHO have urged the scientific community to search for new approaches to combat antibiotic resistance.
Antibiotic drug discovery is hampered by several intrinsic factors.For instance,the permeability barrier provided by the outer membrane of Gram-negative bacteria typically leads to more resistant strains compared to Gram-positive bacteria. Since the outer membrane hinders the antibiotics from gaining access to their targets inside the bacterial cell, the development of antibiotics to treat infections caused by Gram-negative bacteria remains ac hallenge.I nt his regard, cationic peptides can increase the permeability of the outer membrane and allow antibiotics to reach their target inside the bacterial cell. [2] Another important aspect of antibiotic drug discovery is the lack of novel antibacterial targets.I n addition to the well-understood and heavily exploited antibacterial targets such as cell wall synthesis or protein synthesis,new targets or modes of action are desperately needed. Recently,t argeting adenosine triphosphate (ATP) synthase has been asuccessful step forward for the treatment of drugresistant strains of Mycobacterium tuberculosis. [3] More examples with novel modes of action, such as targeting antibiotic resistance at the genetic level, will be discussed in this Review.
Alot of the research for new antibiotics is still focused on developing improved versions of existing molecules.W hile some of these are simply "me-too" versions of drugs with only Finding strategies against the development of antibiotic resistance is amajor global challenge for the life sciences community and for public health. The past decades have seen ad ramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases,even lastresort antibiotics have lost their power.Inaddition, industry pipelines for the development of novel antibiotics have run dry over the past decades.Arecent world health daybythe World Health Organization titled "Combat drug resistance:n oa ction today means no cure tomorrow" triggered an increase in researchactivity,and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.
moderately better activity,s ome have been developed through logical and systematic changes that make them more efficient or less susceptible to resistance mechanisms. Screening for novel antibiotics from natural sources is another way to broaden our possibilities for treating infections,b ut this does not eliminate the intrinsic risk for the development of resistance to these novel antibiotics.A mechanistic and structural understanding of bacterial resistance offers much better opportunities for tackling this problem because this allows the origin of the problem to be addressed rather than simply generating additional resistance in the future.C ombining mechanistic information on resistance with rational structure-based drug discovery approaches enables antibiotic resistance to be bypassed or even suppressed. This strategy has been applied lately with increasing success and will be the focus of this Review.
Structure-based design has developed into am ature technique in drug discovery.T his has been fueled by Luka Raguž received his BSc in chemistry in 2011 and his MSc in chemistry for the life sciences in 2013 from the Zurich University of Applied Sciences (ZHAW). Forhis master's thesis, he worked on the structure-based design and synthesis of novel protease inhibitors in the group of Prof. Riedl. After his studies, he continued in the group of Prof. Riedl as aresearch assistant to work on the development of novel strategies to combat antibiotic resistance. at remendous amount of crystallographic structural data for biological target macromolecules and backed up by genomics data from sequencing campaigns.O nce the structure of at arget or ac o-crystal structure of at arget together with ab ound ligand is available,s tructure-based design can be applied both rationally and creatively in order to tailor the properties of ad rug molecule.F ragment-based approaches are used for the identification of chemical starting points for lead optimization, virtual docking allows in silico screening, and de novo approaches generate new chemotypes for drug molecules. [4] [5] [6] [7] [8] Several excellent and comprehensive review articles about antibiotics have appeared in this journal as well as others.T heir focus has been, among other things,o nt he discovery and synthesis of antibiotics and on the evolution of antibiotic resistance. [9] [10] [11] [12] [13] In this Review,w eh ighlight structure-based approaches that have successfully been applied to combat antibiotic resistance.T his includes several target classes and different structure-based techniques in order to depict the broad applicability of this strategy.Our selection is predominantly based on examples that have already delivered clinical drug candidates and can serve as showcase projects for the antibiotic research community.I na ddition, we have also included the results of very recent collaborations in this field that have not yet delivered clinical candidates,b ut have delivered promising techniques and scientific concepts in order to stimulate the scientific discussion.
Owing to the high amount of structural data in this Review,t he preparation of this manuscript required heavy use of graphics and modeling software.F or the depiction of co-crystal structures and structural models,weused Chimera 1.10.1 [14] along with Inkscape [15] for labeling.M olecular docking was done with AutoDock Vina 1.1.2. [16] 
Protein Synthesis Inhibitors
Theb acterial protein synthesis machinery is am ajor target for antibiotics and it has been used for efficient structure-based interventions against antibiotic resistance. [17, 18] Protein synthesis,which is conducted by ribosomes, converts mRNAinto the corresponding polypeptide chain. [19] This process can be divided into four steps:i nitiation, elongation, termination, and recycling.T he first two are depicted in Figure 2a nd will be described here briefly because they provide several targets for antibiotic intervention.
Bacteria have 70S ribosomes that are made up of two subunits. [19] [20] [21] [22] Thel arge 50S subunit, which includes the 23S and 5S rRNAs,binds aminoacyl tRNA( aa-tRNA), catalyzes peptidyl transfer,a nd controls the elongation process,w hile the smaller 30S subunit, which includes the 16S rRNA, binds mRNAa nd initiates protein synthesis.T he initiation step involves assembling these two subunits around the mRNA and the initiator fMet-tRNA. This process is catalyzed by three prokaryotic initiation factors:I F1, IF2 and IF3. The resulting 70S initiation complex has three main tRNAbinding sites,t he A, P, and Esites.T he Asite is the site at which the charged aminoacyl-tRNAmatching the mRNAcodon enters the ribosome.T he Psite carries the peptidyl-tRNA, the tRNAcarrying the growing peptide chain. TheEsite harbors the deacylated or uncharged tRNAb efore it exits the ribosome.T he elongation step is the cycle that adds amino acids to the growing peptide chain in astepwise manner and can be considered the heart of protein synthesis.I nt he first step,aternary complex composed of aa-tRNA, the elongation factor Tu ,a nd guanosine triphosphate (aa-tRNA·EF-Tu ·GTP) binds at the Asite.A fter successful decoding,t he complex is hydrolyzed, thereby resulting in the departure of EF-Tu·GDP (GDP:guanosine diphosphate) and an inorganic phosphate (Pi), which allows the aa-tRNAtoenter the Asite and bind. Peptide bond formation then occurs through transfer of the entire peptide chain from the peptidyl-tRNA in the Psite to the aa-tRNAi nt he Asite.T his pretranslocation ribosomal state (PRE state) is often referred to as ah ybrid state since the tRNAs are moving back and forth between the A/A, P/P,A /P and P/E sites.I nt he next step,e longation factor G( EF-G) catalyzes translocation of the tRNA 2 ·mRNAc omplex by ad istance of one codon (POST state). This results in the deacylatedt RNAb eing moved to the Esite,t he peptidyl-tRNAb eing moved to the Psite,and the Asite becoming free to bind the next aa-tRNA. Until as top codon enters the Asite,t his cycle continues, gradually building the full peptide chain. As seen in Figure 2 , protein synthesis is targeted by anumber of different classes of antibiotics at essentially every step of the process.W hile some classes of antibiotics such as macrolides,oxazolidinones, and pleuromutilins bind the large 50S subunit, others such as aminoglycosides and tetracyclines interfere with the smaller 30S subunit.
Oxazolidinones
Oxazolidinones are the only new class of synthetic antibiotics to be discovered and introduced into the clinic over the past 50 years. [23] They were first discovered in 1978 (E. I. duPont de Nemours &C o.) [24] but later abandoned owing to serious toxicity issues. [25] Research continued in this area (initiated by Upjohn, later Pharmacia, now Pfizer Inc.), and by 1996, two nontoxic oxazolidinones,l inezolid and eperezolid, had been developed (1 and 2;F igure 3). [26] These two molecules were the results of awide structureactivity relationship (SAR) study that revealed the required substitution on the central oxazolidinone core. [27] Essential factors for antibacterial activity were the N-aryl substituent, the 5S configuration, and the C5 acylaminomethyl group.The meta-fluoro substitution of the phenyl ring was not essential, but usually helped to increase activity,a nd the para-substitution could be varied to expand the antibacterial spectrum.
While oxazolidinones are protein synthesis inhibitors that bind to the ribosome,i th as taken an umber of years to identify the binding site and most likely mode of action. [28] In 2008, two reported X-ray co-crystal structures of linezolid bound to 50S ribosomal subunits confirmed the previously established site of action and suggested am ode of action ( Figure 4 ). [29, 30] Linezolid binds to the A-site pocket of the 50S subunit at the peptidyl transferase center (PTC) in actively translating bacterial ribosomes and interferes with binding of the charged aminoacyl tRNA. Specifically,l inezolid binds to ap ocket formed by eight RNAr esidues,o ne of which, U2585Ec,i s stabilized in ad istinct conformation. By stabilizing U2585Ec in anonproductive conformation, linezolid affects the binding and/or positioning of the initiator-tRNAa nd prevents the binding of tRNAatthe Asite,thereby halting the translation sequence ( Figure 4A ). [29] Resistance to oxazolidinones is still relatively rare.Sofar, three classes of oxazolidinone resistance mechanisms have been characterized. [31] Thefirst involves mutations in the 23S rRNAc entral loop of domain V, the peptidyl transferase center. While some of the mutated residues interact directly with the oxazolidinone,m any do not but are instead used to stabilize the region surrounding the oxazolidinone. [28] Mutations in these residues lead to small conformational changes of the linezolid binding pocket, which adversely affects drug binding.T he second mechanism, which is less common, involves mutations in the genes rplCand rplD, which encode ribosomal proteins L3 and L4, respectively. [31] Beyond these chromosomally encoded point mutations, the last mechanism involves acquisition of the ribosomal methyltransferase gene cfr (chloramphenicol-florfenicol resistance). This resistance is more worrisome than the mutation-based mechanism since it is horizontally transferable and carries al ow fitness cost. [32, 33] Mechanistically,t he methyltransferase Cfr,t hrough C8 methylation of the key residue A2503Ec in the 23S rRNA, greatly reduces susceptibility to aw ide range of ribosome-targeting antibiotics, including amphenicols,l incosamides,p leuromutilins,s treptogramin A, 16-membered macrolides,a nd linezolid. [34] As seen in Figure 4B ,the addition of amethyl group on A2503Ec leads to as teric clash with the acetamide group of linezolid, thereby causing atwo-to eight-fold increase in the minimum inhibitory concentration (MIC). [36] Since the discovery of linezolid, over 30 companies have advanced more than ad ozen candidates in clinical development. Unfortunately most of these have failed owing to issues related to pharmacokinetic (PK) properties,s afety profile,s olubility, or lack of improvement of antimicrobial activity over linezolid. Therefore the two main challenges for successful second-generation oxazolidinones are minimizing the myelosuppression safety signal and achieving adequate activity against linezolid-resistant strains of bacteria. [31] Tw os econdgeneration oxazolidinones that attempt to solve these problems in arational way will be presented herein.
Tedizolid
Te dizolid phosphate (3;p reviously torezolid phosphate, TR-701, DA-7218) is the inactive prodrug of tedizolid (4; previously torezolid, TR-700, DA-7157, which was discovered by Dong-A Pharmaceuticals,a nd developed by Trius Therapeutics and Cubist Pharmaceuticals). [37, 38] After two successful phase III trials,t edizolid was approved by the Food and Drug Administration (FDA) in June 2014 under the trade name Sivextro for the treatment of MRSA skin infections ( Figure 5 ). Structurally,t edizolid presents two main differences compared to linezolid:s ubstitution of the acylaminomethyl group at C5 by ah ydroxymethyl moiety and introduction of the C/D ring system, here a6 -(2-methyl-2H-tetrazol-5-yl)pyridine ( Figure 5 ). Thei ncrease in lipophilicity brought by the addition of the Ca nd Dr ings obliged the medicinal chemists to find an adequate prodrug that would solve the low aqueous solubility and oral bioavailability problems. [37] A series of formulations was evaluated and the monophosphate ester was found to have the best properties (high water solubility and improved bioavailability) while also masking the primary alcohol, which provided ag reatly improved monoamine oxidase inhibition profile. [31] Thee ffect that these structural modifications bring to tedizolid can be clearly seen in Figure 6 . At the bottom end of the binding site,t he methylated A2503Ec is able to accommodate the sterically compact hydroxymethyl group while still maintaining the hydrogen bonding with G2505Ec.Additionally,t he proposed binding model predicts two new (1)int he 50S ribosomals ubunit from H. marismortui that has been methylatedb yCfr at A2503Ec. The surface clash is highlighted in red. Escherichia coli numbering in parentheses. Model was generated with Chimera 1.10.1 accordingt o K. J. Shaw et al. [14, 35] stabilizing hydrogen bonds between the C/D ring system and the backbone ribose sugars of A2451Ec and U2584Ec.
In as tudy of its activity against linezolid-resistant staphylococci, tedizolid showed amore than 16-fold improvement compared to linezolid. [39] It also maintained activity against most of the tested isolates,including multidrug-resistant ones, thus clearly demonstrating the benefit of the structure-based approach.
Radezolid
Radezolid (5;p reviously RX-1741 and Rx-01_667; Figure 5 ) is af ully synthetic oxazolidinone (developed by Melinta Therapeutics,f ormerly Rib-X) that has completed two phase II clinical studies. [40] Radezolid is the result of ap rogram developed to expand the spectrum of oxazolidinones to Gram-negative bacteria and optimize drug-like properties. [41] Thep rogram started with the observation that linezolid and sparsomycin (6,an on-selective antibiotic) had overlapping binding sites within the peptidyl transferase center of the 50S ribosomal unit (Figure 7 ). [42, 43] Thes trategy was therefore to link the two molecules together via an adequate bridging element and make the required structural modifications on the sparsomycin side to increase potency and selectivity. [41, 44] Figure 8s hows two (7 and 8)o ft he numerous bridged antibiotics that were synthesized on the road to radezolid and clearly shows the evolution of the western half and the bridging unit.
Once the optimal structural elements were determined, the activity of radezolid was assessed and it was found to bind with higher affinity to the ribosome than linezolid, which gave it enhanced antibacterial activity (2-8-fold improvement over linezolid) against various Gram-positive pathogens. [45] Structure-activity studies of diverse oxazolidinones revealed that despite the presence of aC 5a cylaminomethyl group in radezolid, it retains activity against the clinical cfr-positive CM05 strain of S. aureus with am inimal inhibitory concentration (MIC) value of 2 mgmL À1 ,w hich is between those of tedizolid (0.5 mgmL
À1
)and linezolid (8 mgmL À1 ). This is most likely due to additional binding interactions of the C/D ring system with the PTC,f ar from the ribosomal modifications that lead to resistance to linezolid, including the cfr-mediated methylation of A2503Ec. [36, 40, 46] Most noteworthy is the fact that the spectrum could be expanded to Gram-negative organisms such as Haemophilus influenzae and Moraxella catarrhalis.A dditional features of radezolid, besides overcoming the ribosomal mutation resistance,include a100-fold decreased activity in inhibiting translation in rabbit reticulocytes than in S. aureus ribosomes and interaction with U2585Ec,asverified by biochemical assay. [40] 
Macrolides
Macrolides are af amily of 14-, 15-, and 16-membered polyketide lactone rings with one or more neutral or amino sugar substituents at various positions ( Figure 9 ). [47] Eryth- Figure 6 . Models of tedizolid (4)(Cg reen, Fpurple) in A) the 50S ribosomals ubunit from H. marismortui (PDB ID:3CPW) and B) the 50S ribosomalsubunit from H. marismortui that has been methylated by Cfr.E ven with methylation at A2503Ec, tedizolid (4), unlike linezolid, is able to bind to the ribosomalRNA. E. coli numbering in parentheses. Models generated with Chimera 1.10.1 and AutoDock Vina 1.1.2 according to K. J. Shaw et al. [14, 16, 35] romycin (9), the first and prototypical macrolide,was isolated from actinomycete bacteria in 1949. [48] It was first used clinically in the early 1950s,b ut owing to its acid instability, second-generation semisynthetic macrolides such as clarithromycin (10) [49] or azithromycin (11) [50] were developed ( Figure 9 ). Subsequently,o wing to the emergence of resistance to first-and second-generation macrolides,athird generation, coined the ketolides,w as developed. In these 14-membered lactone rings,t he cladinose sugar at C3 is replaced by aketone moiety,C11 and C12 are now part of an oxazolidinone ring, and an alkyl-aryl side chain is appended to the macrolactone core.T elithromycin (12)i st he only registered ketolide to date ( Figure 9 ).
Like many other antibiotic classes,macrolides are bacteriostatic. They bind to the 50S ribosomal subunit in the vicinity of the peptidyl transferase center just above the constriction formed by the extended loops of ribosomal proteins L4 and L22 and were originally thought to inhibit protein synthesis by completely obstructing the ribosomal tunnel. [51] In fact, modeling studies have shown that even with abound macrolide,t he tunnel can still accommodate an ascent peptide chain. Them acrolide nevertheless greatly hinders the progression of the peptide,w hich is usually dissociated by the peptidyl-tRNAd rop-off mechanism before reaching its full size. [51, 52] Macrolides have also been shown to block the formation of the large 50S ribosomal subunit by binding to its precursors. [53] Anumber of co-crystal structures of macrolides bound to the ribosome have been published and they show that the main component in the binding pocket is A2058Ec. [54] [55] [56] Key interactions include polar contacts between the functional groups of the C5 desosamine sugar and residues A2058Ec and A2059Ec,a sw ell as hydrogen bonds between the three lactone hydroxy groups and the 50S ribosomal subunit ( Figure 10 ).
Bacteria have developed an umber of mechanisms of resistance to macrolides. [57] Even though the majority of them involve alterations at the ribosomal target site,s ubstrate inactivating enzymes (mainly esterases) and efflux mechanisms have also been reported. Alteration of ribosomal binding sites usually leads to failure of the antibiotic to bind, which in turn disrupts its ability to inhibit protein synthesis.In the case of macrolide resistance,these alterations mainly take place in one of two ways.T he first, which has the smallest effect, is modification of the ribosomal proteins L4 and L22 at the end of their hairpin structures,close to the binding site. [58] Interestingly,m utations at L4 lead to large reductions in the binding affinity while the L22 mutants show no change in the binding constant but still confer resistance.T his is explained by aw idening of the tunnel, which allows passage of the peptide without affecting the binding. [59] Thesecond and most common resistance mechanism is modification of the rRNA. This takes place,u nsurprisingly,o nA 2058Ec,t he key component of the binding pocket. Mono and dimethylation of A2058Ec are carried out by erythromycin ribosome methylation (Erm) methyltransferases. [60] While monomethylation confers only moderate resistance to macrolides and none to ketolides,d imethylation leads to complete blocking of the binding site and high resistance to both macrolides and ketolides. [18, 61] Mutation of A2058Ec into G2058Ec also induces resistance owing to the similar increase in steric bulk. Notably,i na rchaea and eukaryotes,p osition 2058Ec is naturally ag uanine,w hich explains the selectivity for bacteria. [62] As mentioned earlier, ketolides were developed in an effort to counter resistance to macrolides.T heir key features include a14-membered macrolactone,the replacement of the C3 cladinose sugar by aketo group,acyclic carbamate and an extended alkyl-aryl side chain ( Figure 11 ). TheC3keto group gives rise to potent activity against strains with Erm-mediated inducible resistance and surmounts resistance through efflux. [63] It also removes some of the steric hindrance around the desosamine sugar, which allows it to reposition itself when binding to monomethylated ribosomes. [64] The Figure 9 . Structures of the three macrolides erythromycin, clarithromycin, and azithromycin, as well as the ketolide telithromycin. Figure 10 . Overview of the binding mode of erythromycin (9;Cgreen) to the 50S ribosomalsubunit (PDB ID:1 JZY) from Deinococcus radiodurans.T he nucleotides are labeled accordingtoD. radiodurans (E. coli in parentheses).
cyclic carbamate introduces additional interactions with the ribosome,w hich stabilize the conformation of the core macrolide and lead to potent antibacterial activity. [65] Crystal structures of ketolides in both D. radiodurans and in H. marismortui have been published and show notable differences in their binding modes. [51, 56, 66, 67] Indeed, when complexed to the ribosome of H. marismortui,t he side chain of telithromycin resides over the plane of the macrolactone ring (PDB ID:1 YIJ) [56] whereas with the ribosome of D. radiodurans,t he side chain points away from the macrolactone core (PDB ID:1 P9X). [66] This clearly highlights the importance of crystallographic data and is ag ood reminder to exercise caution when using models.N evertheless,t he common feature is that the ketolides not only bind to domain Vi nasimilar fashion as macrolides,b ut their elongated side chains engage in additional interactions in domain II. This results in tighter binding and allows them to compensate for modifications in domain Vr esulting from mutation or methylation.
Te lithromycin (12)i sc urrently the only ketolide on the market, but following safety controversies,i th as been partially withdrawn. [68] Its use has been associated with severe hepatotoxicity along with blurred vision and serious cases of liver failure. [69] These are believed to result from inhibition of the nicotinic acetylcholine receptors.T he pyridine ring in the extended side chain of telithromycin has been suggested to be the culprit. [70] New ketolides lacking this problematic pyridine ring are currently being investigated.
Solithromycin
Solithromycin (13;p reviously CEM-101, developed by Cempra) is a2-fluoroketolide currently undergoing phase III clinical trials.A ss een in Figure 11 , solithromycin is very similar to telithromycin, with only two minor modifications. Thef irst is replacement of the aforementioned problematic imidazolyl pyridine with atriazolyl aniline,and the second is the introduction of af luorine atom at the C2 position. Removal of the imidazolyl pyridine resulted in a3 0-fold reduction in the inhibition of nicotinic acetylcholine receptors compared to telithromycin. [70] As mentioned earlier,previous X-ray structures of ribosome-bound ketolides showed very different orientations of their alkyl-aryl side chains depending on the bacterial species.T herefore,questions remained as to the actual binding mode of solithromycin and telithromycin in pathogenic bacteria. In 2010, Cate,M ankin, and co-workers crystallized solithromycin as well as telithromycin in complex with the E. coli ribosome and were able to indicate that the placement of these ketolides most likely reflects the binding in S. aureus ribosomes given the sequence conservation of the A752:U2609 base pair among many eubacteria. [71, 72] These crystal structures delivered revealing insight into various aspects of the interaction ( Figure 12 ). As tacking interaction can be seen with the A752:U2609 base pair, which is present in the ribosome of E. coli and many other pathogenic bacteria. Thea niline moiety,w hich replaces the detrimental pyridine is shown to form additional hydrogen bonds,n otably to A752 and G748, and results in tighter binding.F inally the fluorine atom at the C2 position was shown to contribute to drug binding as well as chemical properties such as solubility and cellular uptake. [73] Indeed, in comparison to non-fluorinated analogues,t he fluorinated versions showed stronger inhibition of the growth of streptococci carrying the erm gene.I nterestingly,f or solithromycin, weak binding to ribosomes dimethylated at A2058Ec could be detected by chemical probing. [71] Key structural features of 
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Thiopeptides
Thet hiopeptides are af amily of highly modified sulfurrich macrocyclic peptides ( Figure 14 , numbering according to thiomuracin A), [76] which have been isolated from diverse sources such as soil bacteria and marine samples. [77] While there are now over 100 known thiopeptides,the first member, micrococcin P1 (14) , was isolated in 1948. [78] These molecules are of ribosomal origin, are highly posttranslationally processed, and feature ac haracteristic macrocyclic core consisting of multiple thiazoles and a6 -membered nitrogen-containing heterocycle,which can be found in different oxidation states.W hile thiopeptides are an ew class of antibiotics with an ovel mechanism of action, their use as an antibiotic treatment option has been hampered by their very large molecular size and poor aqueous solubility.T hiopeptides are inhibitors of protein synthesis,but their mode of action differs depending on the size of the macrocycle.T hiostrepton A (15), [79] the archetypal thiopeptide,a nd micrococcin P1 possess 26-membered macrocyclic cores and are known to bind to the GTPase-associated region of the ribosome/L11 protein complex. [80] Thiopeptides with 29-membered macrocyclic cores such as GE2270 A( 16), on the other hand, interact with GTP-bound bacterial EF-Tu, preventing the formation of the ternary complex with aa-tRNA. [81] GE2270 Aw as isolated in 1991 by scientists at Lepetit Research Institute. [82] Although the in vitro activity of this compound was shown to be excellent against MRSA, VRE, and streptococci, poor aqueous solubility prevented further development. [83] Twod erivatives are currently being investigated.
LFF571
In order to increase the water solubility of GE2270 A, the unstable oxazoline side chain was replaced with solubilizing functional groups (Novartis). The4 -aminothiazolyl moiety was chosen as as tarting point and aw ide variety of amines and acids linked via different spacers were synthesized. [83] [84] [85] Guided by co-crystal structures with EF-Tu, this search led to the discovery of two potent analogues with cyclohexylcarboxylic acid side chains residing in proximity to the Arg223 residue of EF-Tu. 
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These compounds were then improved by the addition of as econd solubilizing group. [86] Taking into account the position of Arg262, al arge variety of differently linked acids were synthesized. It was found that ap entanoic acid residue appended onto the aminothiazole was the best since it placed the acid in proximity to this residue ( Figure 15 ). The resulting compound, named LFF571 (17), also showed very high aqueous solubility (> 10 mg mL À1 ). Tr iacid-containing analogues were also synthesized but these both failed to yield additional benefits and greatly increased the synthetic complexity,a nd they were therefore not pursued. LFF571 is currently undergoing phase II clinical trials against C. difficile infections.
NVP-LDU796
In 2009, the isolation of thiomuracins,anovel class of antibiotic thiopeptides,w as reported (Novartis). [76] These secondary metabolites,w hich are produced by as train of Nonomuraea,are structurally related to GE2270 Aand share the same mechanism of action, namely binding to EF-Tu. The thiomuracins show potent antibiotic activity against MRSA and VRE, with minimum inhibitory concentrations below 1 mgmL À1 .U nfortunately,a sw ith GE2270 A, these novel molecules are plagued by solubility and stability problems.In 2012, the same group reported the synthesis of an ovel derivative of thiomuracin A(18), termed NVP-LDU796 (19) , which retains antibacterial activity and shows improved chemical stability and physiochemical properties ( Figure 14) . [87] Key modifications include removal of the C2-C10 side chain and conversion of the C84 epoxide into an N70-C84 pyrrolidine ring. In co-crystal structures of NVP-LDU796 (19)w ith EF-Tu, the conformation adopted is very similar to the those of GE2270 Aa nd LFF571, with key interactions still present (PDB ID:4G5G). [87] 2.4. Tetracyclines Te tracyclines are broad-spectrum antibiotics with activity against both Gram-positive and Gram-negative bacteria. [88] Chlortetracycline (20) , the oldest member of this class,w as discovered in 1945 and first used clinically in 1948 (Figure 16 ). [89] Since then, only three other naturally occurring tetracyclines have been discovered (tetracycline (21), [90] oxytetracycline (22) [91] and demethylchlortetracycline (23) [92] ), while countless others have been derived semisynthetically,i ncluding doxycycline (24) [93] and minocycline (25) . [94] Te tracyclines are easily recognizable by their four highly oxygenated fused rings and they show favorable antimicrobial properties along with an absence of major side effects,w hich has led to their extensive use in both human and animal infections.T he third generation of tetracyclines,t he glycylcyclines (Figure 17 ), were introduced 10 years ago,w ith the first and so far only clinically used member being tigecycline (26,p reviously GAR-936, discovered at Wyeth-Ayerst Research). [95] Glycylcyclines can be recognized by the glycylamido substituent on the C9 carbon. The tert-butylglycylamido moiety of tigecycline engages in stacking interactions with C1054 of the 16S rRNA, which leads to increased potencyof tigecycline compared to tetracycline (Figure 18 ). [96] Te tracyclines are primarily bacteriostatic.T hey penetrate the outer membrane of Gram-negative bacteria by passive diffusion through the OmpF and OmpC porin channels as divalent metal-ion chelates. [88] Once inside the periplasm, the liberated neutral tetracycline diffuses through the inner Angewandte Chemie Reviews membrane in the same way that it penetrates Gram-positive bacteria and other organisms,n amely by energy-dependent active transport. Once inside the cytoplasm, the higher pH and metal-ion concentration lead to the regeneration of am etal-ion/tetracycline complex that is postulated to be the active species.T his complex then binds reversibly to the Asite on the head of the 30S subunit ( Figure 18 ). [96, 97] This binding site has aslight overlap with the anticodon stem-loop, which correlates well with previous observations that tetracycline prevents binding of the aforementioned aa-tRNA·EF-Tu ·GTP ternary complex to the Asite. [98] Resistance to tetracyclines can occur through four different mechanisms. [88] Theproteins responsible for three of these mechanisms are encoded by the tet (tetracycline) and otr (oxytetracycline) genes,o ver 40 of which have been characterized. Of these,o nly three,n amely tet(X), tet (34) , and tet(37), lead to an enzymatic-alteration resistance mechanism where the encoded proteins chemically modify tetracycline. [88] Of the remaining genes,a pproximately two thirds encode efflux proteins and the others encode ribosomal protection proteins (RPPs). Thee fflux proteins occur in both Grampositive and Gram-negative bacteria, but are more prominent in the latter. They are membrane-associated proteins and export tetracyclines from the cell, which effectively protects the ribosome by reducing the intracellular concentration of the antibiotic.Ribosomal protection proteins are cytoplasmic proteins that protect the ribosome from the action of tetracyclines by reducing their susceptibility.T hey are also found in both Gram-positive and Gram-negative bacteria, but they are usually more common in Gram-positive organisms, and tet(M) and tet(O) are the two most common genotypes. Mechanistically,t hese proteins cause allosteric disruption of the primary tetracycline binding site,w hich leads to the release of bound tetracycline molecules. [99] Ther ibosome is then able to return to its productive conformation and resume protein synthesis.T he last and most recent mechanism of resistance involves mutations in the vicinity of the tetracycline binding site. [100] Thep resence of the tert-butylglycylamido moiety in tigecycline (26)i nterferes with the binding of Te tM to the ribosome and thereby enables the drug to overcome TetMmediated resistance.A ss hown in Figure 19 , tigecycline and Te tM overlap in the ribosome owing to the bulky tertbutylglycylamido substitution of the drug molecule. [96] 2.4.1. Omadacycline Omadacycline (27;p reviously PTK-0796, Paratek Pharmaceuticals,F igure 17) is as emisynthetic tetracycline derivative and the first member of the novel aminomethylcycline class.Itiscurrently undergoing phase III clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and complicated urinary tract infection (cUTI). Omadacycline has been shown to be active against strains that express either efflux proteins (tet(K)) or ribosome protection (tet(M)), while also exhibiting moderate inhibition of peptidoglycan synthesis. [101, 102] Thee xact mechanisms by which omadacycline evades both efflux and ribosome protection are not fully known, but it is believed that omadacycline is apoor substrate for efflux transporters and that it binds in aunique way that circumvents the action of ribosome protection proteins. [101] Both of these factors almost certainly arise from the structural modification at C9 of the tetracycline core.
Aminoglycosides
Aminoglycosides are hydrophilic molecules comprised of ac entral aminocyclitol core linked to one or more amino sugars.I nm ost cases,t he aminocyclitol is streptamine or 2-deoxystreptamine (28 and 29,F igure 20). Depending on the substitution pattern, aminoglycosides can be grouped into four different subfamilies:monosubstituted (such as neamine (30)), [103] atypical, 4,5-disubstituted, and 4,6-disubstituted ( Figure 20) . [104] Thea minoglycoside family of antibiotics is one of the oldest, with its first member,s treptomycin (31), being discovered more than 70 years ago in 1944. [105] Despite their long history,w idespread resistance,a nd possible safety issues such as nephrotoxicity and ototoxicity,aminoglycosides are still widely used.
[106] Figure 18 . Overlay of tetracycline( 21;Cyellow; PDB ID:4V9A) and tigecycline (26;Cgreen, Mg 2+ ions light brown;P DB ID:4V9B) bound to the 30S ribosomals ubunit (PDB ID:4 V9B) from Thermus thermophilus.Tigecycline makes additionals tacking interaction with C1054 compared to tetracycline. T. thermophilus numbering is used for the nucleotides. Figure 19 . Overlay of TetM (blue ribbon;PDB ID:3 J25) and tigecycline (26;Cgreen, Mg 2+ ions light brown;P DB ID:4 V9B) bound to the 30S ribosomals ubunit (PDB ID:4 V9B) from T. thermophilus.T he superimposition was generated by means of the cryo-electron microscopy density map EMD-2183 of the TetM-70Scomplex from E. coli according to Jenner et al. and Dçnhçfere tal. [96, 99] Angewandte Chemie Reviews Thea minoglycosides have two distinct main mechanisms of action. They are not only potent inhibitors of translocation but are also able to induce misreading by stabilizing the binding of near-cognate tRNAs and promoting their incorporation into peptide chains. [104] Theh igh fidelity of translation (error frequencies ranging from 10 À3 to 10 À4 per codon) [107] is achieved by the ability of the ribosome to select the proper (cognate) tRNAo ver aw rong (noncognate) one at the Asite.
Thestructure of the 30S ribosome shows a"decoding" site within helix 44 (h44) of the 16S rRNA. In this asymmetric internal loop,t wo universally conserved adenine residues, A1492 and A1493, are directly involved in the decoding process,during which they flip out of the helix to analyze the codon-anticodon complex. [108] Theenergy needed for this flip is thought to be compensated by stabilizing interactions between the nucleotides and the codon-anticodon complex, but only in the case of acognate tRNA. When anon-or nearcognate tRNAbinds,the energy compensation is insufficient and the tRNAd issociates.U pon binding within the internal loop of h44, aminoglycosides induce al ocal rearrangement that flips A1492 and A1493 out of the helix and stabilizes them in this open conformation (Figure 21) . [109] This results in near-cognate tRNAb eing fully accommodated in the Asite, with the consequence that incorrect amino acids are incorporated into the peptide chain.
When the altered proteins are inserted into the cell membrane,t he permeability is modified, which in turn leads to an increase in aminoglycoside uptake (hence their high bactericidal and concentration-dependent activity). Co-crystal structures of avariety of bound aminoglycosides have been published, including with streptomycin (31,P DB ID: 1FJG), [110] spectinomycin (32,P DB ID:1 FJG), [110] hygromycin B( 33,P DB ID:1 HNZ), [97] neomycin B( 34,P DB ID: 4V52), [111] paromomycin (35,P DB ID:1 FJG,1 IBK), [110, 112] tobramycin (36,P DB ID:1 LC4), [113] and kanamycin A( 37, PDB ID:2ESI). [109] Bacteria have developed three different mechanisms of resistance to aminoglycosides:u ptake inhibition or efflux, ribosome modification, and aminoglycoside modification. [114] Thef irst two mechanisms are relatively rare and have not been targeted yet. Aminoglycoside-modifying enzymes (AMEs), on the other hand, are widespread and the most common mechanism of resistance.T hese enzymes are described according to the modification they promote,a long with the carbon atom at which the modification takes place. [115] Thethree known types of enzymes are aminoglycoside N-acetyltransferases (AACs), aminoglycoside O-nucleotidyltransferases (ANTs), and aminoglycoside O-phosphotransferases (APHs). Figure 22 shows the co-crystal structure of kanamycin A( 37,F igure 20) with the aminoglycosidemodifying enzyme ANT(2'')-Ia. [116] The2 '' hydroxy group is complexed to the magnesium ion, ready to be modified by the enzyme.
Asecond generation of aminoglycosides called neoglycosides, [117] which maintain the potencyo ff irst-generation aminoglycosides while evading modification enzymes,i s currently being researched.
Plazomicin
Tw oa minoglycosides,s isomicin [118] and amikacin [119] (38 and 39;F igure 23), were used as inspiration for the development of the semisynthetic plazomicin (40,f ormerly ACHN- 490, developed by Achaogen), which is the first molecule of this new family (Figure 24 ). [117] Thed ifference between sisomicin and plazomicin is the presence of two side chains on the nitrogen atoms at C1 and C6' in plazomicin. As highlighted in Figure 24 , the hydroxyethyl chain shown in red blocks AAC(6'), while the amikacin-derived hydroxyaminobutyric acid (HABA) chain shown in blue blocks AAC(3) along with ANT(2'')a nd APH(2''). [120, 121] Compared to kanamycin A, plazomicin is also protected from APH(3')and ANT(4')bythe absence of hydroxy groups at positions C3' and C4'.T he only aminoglycoside-modifying enzymes that plazomicin is still vulnerable to are AAC(2')e nzymes,b ut so far the expression of these enzymes has been detected only in Providencia stuartii. In MDR Enterobacteriaceae,including carbapenem-resistant Enterobacteriaceae (CRE), plazomicin remains active where most other antibiotics,i ncluding the commercially available aminoglycosides,s how limited potencyo wing to resistance.
Cell Wall Synthesis Inhibitors
Theb acterial cell wall is made of peptidoglycan, itself composed of strands of glycan units linked by peptides.I ts synthesis takes place in three steps,starting in the cytoplasm, passing through the inner-membrane,a nd ending in the periplasm (Figure 25 ). Them echanism of this synthesis has been thoroughly studied and will only be briefly discussed here. [122] Thei nitial precursor,U DP-MurNAc,i sg enerated from UDP-GlcNAc by the action of the transferase MurA and the reductase MurB.T othis glycan, five amino acids are then attached sequentially by the ligases MurC-MurF.T he last two d-Ala residues are generated from l-Ala by the alanine racemase Alr and linked to the chain by the alanine ligase Ddl. TheM urNAc pentapeptide is then transferred to an undecaprenyl pyrophosphate by the translocase MraY, followed by the addition of aG lcNAc unit by the glycosyltransferase MurG to give Lipid II. Finally five l-Gly units are attached to Lipid II by the acyltransferases FemX, FemA, and FemB.L ipid II is then transferred from the cytoplasm to the periplasm through the inner membrane by flippases such as FtsW and RodA. Once in the periplasm, Lipid II is incorporated into the peptidoglycan cell wall by the action of two successive penicillin-binding proteins (PBPs). Thef irst, at ransglycosylase,c atalyzes polymerization of the glycan strands,w hile the second, at ranspeptidase,c rosslinks the glycan strands into athree dimensional mesh.
Al arge number of antibiotics target the synthesis of peptidoglycan or its precursors,w hich results in cell death ( Figure 25 ). Eukaryotic cells do not possess ap eptidoglycan cell wall, which makes these antibacterial agents selective for bacteria.
Glycopeptides and Lipoglycopeptides
Va ncomycin (41,F igure 26), the prototypical glycopeptide,w as isolated in the 1950s from microbes found in soil samples (Eli Lilly and Company) [123] and its structure was determined in the early 1980s. [124] It is ah ydrophilic rigid glycopeptide with poor absorption in the gastrointestinal (GI) tract. It was first used in the clinic in 1959, but owing to its toxicity,i tw as usually only used as al ast resort. While resistance was slow to develop,h igh-level resistance was reported in 1986 in enterococci. [124] Glycopeptides all share acommon mode of action, which consists of binding to the C-terminal d-alanyl-d-alanine of peptidoglycan precursors. [125] This was first discovered in vancomycin in the late 1960s and then confirmed by NMR studies by the Williams group in 1983. [126] More recently,these results have been confirmed by X-ray crystallography. [127] [128] [129] 
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Ther esulting steric hindrance from this binding inhibits the transglycosylation and transpeptidation steps in cell wall synthesis ultimately resulting in bacterial cell death ( Figure 26 ). [125] To circumvent glycopeptides such as vancomycin, bacteria have developed numerous mechanisms of resistance,the most common phenotype being Va nA. [130] This phenotype shows substitution of the d-Ala-d-Ala terminus on peptidoglycan residues by d-Ala-d-Lac. Va ncomycin can therefore only form four of the usual five hydrogen bonds with the resulting depsipeptide,t he last one being replaced by ad estabilizing lone-pair/lone-pair interaction. [130] This seemingly small change results in reduction of the binding affinity between the antibacterial agent and the target by up to 1000 fold. [130] 3.1.
Vancomycin Analogues
TheBoger group at Scripps has carried out atremendous amount of work on the synthesis of vancomycin and its analogues,focusing on binding to d-Ala-d-Lac strands. [131] In resistant bacteria, peptidoglycans with the d-Ala-d-Lac terminus only make four hydrogen bonds with vancomycin, resulting in a1000-fold loss in binding affinity.This figure can be divided into two factors:a10-fold decrease as ar esult of the loss of ahydrogen bond, and a100-fold decrease owing to repulsion of the lone pairs on the two nearby oxygen atoms. [132] In order to try and regain the lost binding affinity, as eries of vancomycin analogues was synthesized with modifications at the carbonyl group of residue 4 ( Figure 27 A) . [131, 133] Thet hioamide equivalent proved to be completely inactive against both vancomycin-sensitive and vancomycinresistant bacteria. This was postulated to be due to the increased bond length and size of the sulfur atom, which presumably prevents binding of the ligand. Ther educed analogue,i nw hich the carbonyl is replaced by am ethylene group,d id not reinstate the lost hydrogen bond but did remove the predominant lone-pair repulsion factor.T his led to an increase in binding affinity for the mutated d-Ala-d-Lac strand. Theb est results were obtained when the amide was replaced by an amidine.I ndeed, as seen in Figure 27 B, the amidine can serve adual role.Inthe case of binding to d-Alad-Ala strands,t he nitrogen atom can take the role of ah ydrogen-bond acceptor,w hereas in the case of binding to d-Ala-d-Lac strands,i tc an serve as ah ydrogen-bond donor. This,incombination with the introduction of alipophilic 4-(4-chlorophenyl)benzyl side chain derived from oritavancin [134] (which allows the antibiotic to anchor into the bacterial cell analogues,r espectively). [133] 
b-Lactams
In 1928, Alexander Fleming discovered the inhibitory effect of a Penicillium mold on the growth of bacteria. [135] Nevertheless,i twasnt until 1941 that penicillin was used for the first time to treat human patients. [136] To this day, b-lactam antibiotics are still widely used around the globe,a nd medicinal chemists have developed numerous variations and generations of this scaffold. [137] Them echanism of action of b-lactams involves covalent binding to transpeptidases, thereby inhibiting cell wall synthesis. [138] Indeed, b-lactams mimic the d-Ala-d-Ala terminal sequence of peptidoglycan chains,t he natural substrate of transpeptidases ( Figure 28, top right) . As seen in Figure 28 , the distance between the two carbonyls of the peptidoglycan chain is very similar to the distance between the carboxylic acid and the b-lactam carbonyl. Thea ntibiotic therefore acts as ac ompetitive antagonist for the transpeptidase enzyme.M echanistically, the hydroxy group of as erine residue reacts with the lactam carbonyl, which leads to opening of the four-membered ring ( Figure 28 , purple cycle). [136] Ther esulting acyl enzyme ( Figure 29 ) is stable,a nd hydrolysis is very slow (low k 3 ), 
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Reviews thus rendering the enzyme inactive and ultimately leading to cell lysis and death. [139] Resistance to b-lactams occurs through four mechanisms. [140] Thef irst two are relatively rare and only occur in Gram-negative bacteria. One involves alteration of the porin channels,which prevents access to the transpeptidases,while the other involves efflux pumps that export the antibiotic. These mechanisms have not been specifically targeted in recent antibiotics.The third and most common mechanism of resistance is the production of b-lactam-hydrolyzing enzymes. These enzymes are structurally very similar to the transpeptidase enzymes and mechanistically function in as imilar manner by opening the b-lactam ring ( Figure 28 , orange cycle). [140] What differentiates the two is the fact that while acyl transpeptidases were slow to hydrolyze,t he acylated blactamases are hydrolyzed at amuch faster rate (high k 3 ). This rapid hydrolysis results in regeneration of the b-lactamase and inactivation of the antibiotic.O riginally, b-lactams were synthetically modified to resist and evade b-lactamases,which led to so many scaffolds and multiple generations of these types of antibiotics.The focus has nowadays shifted to the use of b-lactamase inhibitors co-administered with b-lactams (see Section 4) .
Thef ourth mechanism of resistance,w hich is present in MRSA, is the presence of an exogenous b-lactam-resistant PBP called PBP2a. Studies on this PBP and the similar PBP2 have provided details on the resistance mediated by PBP2a. [141, 142] Theb inding pocket for the antibiotic in PBP2a exists in an unreactive conformation since the active serine (Ser403) is misaligned and acylationd oes not take place.Itwas postulated that only under acidic conditions or if the b-lactam possesses ab ulky hydrophobic substituent, would acylationt ake place. [143] Indeed, allosteric interactions are required to trigger ac onformational change that opens the active site.Following these findings,three so-called "fifthgeneration" cephalosporins,n amely ceftaroline, [144] ceftobiprole, [145] and ceftolozane, [146] were developed by following the currently known SAR (Figure 30 ), and these show activity against MRSA.
Ceftaroline
Ceftaroline fosamil (42;p reviously PPI-0903, TAK-599, Forest Laboratories) is the prodrug of ceftaroline (43), an ovel broad-spectrum cephalosporin approved by the FDAi n2 010 (Figure 31 ). Like other b-lactams,i ts hows bactericidal activity against Gram-positive organisms but also against MRSA.
Ceftaroline was developed by modifying cefozopran (44), af ourth-generation cephalosporin. As seen in Figure 31 , the western half remains mostly unchanged, with the 1,2,4-thiadiazole and oxime moieties still present for Gramnegative penetration and b-lactamase resistance,r espectively. [144] Once bound, ceftaroline has been shown to undergo hydrolysis at avery slow rate. [144] Thephosphono group in the prodrug ceftaroline fosamil is used to increase water solubility 
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Reviews and is rapidly cleaved in the plasma to deliver the active drug ceftaroline. [147] Forc eftaroline,a na llosteric binding site at PBP2a has been identified by crystallographic analysis (Figure 32 ). Thea llosteric binding site (Figure 32 C) is separated from the active site (Figure 32 B) by ar emarkable 60 distance (Figure 32 A) . [148] Crystallographic analysis also revealed the identity of other allosteric ligands for PBP2, such as muramic acid (a saccharide component of the peptidoglycan). Therefore,ithas been proposed that the function of the allosteric domain is to sense nascent peptidoglycan and then open the active site to catalyze the transpeptidation. [148] The elucidation of the ability of the anti-MRSA b-lactam antibiotic ceftaroline and other molecules to trigger allosteric opening of the active site so that PBP2a can be inactivated by as econd b-lactam molecule,s hould enable future structurebased design campaigns for b-lactam antibiotics.
After the introduction of ceftaroline to the clinic, clinical strains resistant to this antibiotic were reported. Tw os ets of mutations within the PBP2a sequence were described (the double mutant N146K/E150K and the triple mutant N146K/ E150K/H351N). [149] These mutations are distant from the active site of PBP2a, hence their functions cannot be understood by aloss of affinity of the antibiotic for the active site of the target protein. Interestingly,t he N146K and E150K mutations are both within the allosteric domain of PBP2a, whereas the H351N mutation is outside of both the allosteric and active sites.B yk inetic studies and by X-ray crystallography of the mutants,Mobashery,Hermoso et al. were able to rationalize that the clinically observed mutations interfere with triggering of the allosteric signal by ceftaroline along the interacting amino acid network between the two sites. [148, 150] These mutations allow the mutant variants of PBP2a to manifest resistance to ceftaroline by two different mechanisms:t he first is am odest increase in the dissociation constant for ceftaroline binding to the allosteric site,a nd the second is disruption of the transmission of conformational changes necessary for opening the active site.T his results in resistance to ceftaroline by an unprecedented mechanism, namely interference with the fidelity of the allosteric response.
[150]
Ceftolozane
Ceftolozane (45;previously CXA-101 and FR264205, discovered at Astellas Pharma, developed by Cubist Pharmaceuticals) is the b-lactam component of the cephalosporin/b-lactamase inhibitor combination Zerbaxa, which was approved by the FDAi nD ecember 2014. [151] As shown in Figure 31 , ceftolozane is derived from the third-generation cephalosporin ceftazidime (46) . It maintains the aminothiadiazole ring and oxime functional groups of ceftaroline and ceftobiprole,which confer enhanced activity against Gram-negative bacilli and stability against b-lactamases,r espectively. [151] Additionally the appended dimethylacetic acid moiety provides improved antipseudomonal activity. [146, 151] On the eastern side,ahighly substituted pyrazole ring provides the steric bulk necessary to reduce hydrolysis by b-lactamases. [151] TheS AR of the substitution pattern of the pyrazole ring was studied in detail, and a5 -amino-1-methyl-1H-pyrazol-2-ium moiety was found to confer the highest antipseudomonal activity. [146] Additionally,the basicity of the substituent at the 3-position of the cephalosporin nucleus could be correlated with improved outer membrane permeability.U nfortunately,t his also led to increased convulsion induction in mice.T he solution was found by introducing basic side chains at position 4o ft he 5-amino-1-methyl-1H-pyrazol-2-ium, with the 2-aminoethylureido group eventually found to have the best balance.
Ceftolozane shows broad-spectrum activity,i ncluding against drug-and multidrug-resistant Pseudomonas aeruginosa,a long with potent antipseudomonal activity. [151, 152] Unfortunately,l ike other oxyimino cephalosporins,i ti s sensitive to extended-spectrum b-lactamases (ESBL) and carbapenemases.F or this reason, ceftolozane is marketed in conjunction with the b-lactamase inhibitor tazobactam (see Section 4), which broadens its spectrum to include ESBLproducing strains of P. aeruginosa and Bacteroides fragilis. [151, 153] Siderophores are small molecules that chelate iron ions, and they allow bacteria to acquire this essential element from the environment for vital cellular processes. [154] Thes iderophore-containing b-lactam BAL30072 (47; Figure 33 , developed by Basilea Pharmaceutica AG) [155] is as iderophore sulfactam conjugate derived from tigemonam (48)w ith an additional dihydroxypyridinone moiety to chelate iron. [156] It serves as ab ioisostere for catechol, and the BAL30072-Fe 3+ complex can thus be actively transported through the outer membrane. [157] Inside the bacteria, it inhibits PBP1a, PBP2a, and PBP3 and acts as an inhibitor of class C b-lactamases. [155] BAL30072 shows good antibacterial activity in vitro against Gram-negative bacteria, is active in vivo against Acinetobacter baumannii,a nd features synergistic activity in combination with carbapenems. [155, 158, 159] In 2014, Starr et al. reported PBP3/BAL30072 co-crystal structures,w hich showed that the siderophore moiety might not be at the ideal position. Indeed, compared to aztreonam (49;F igures 33 and 34 A), [160] another similar monobactam, the molecule misses some favorable interactions,such as asalt bridge with Arg489 and ah ydrophobic pocket interaction with the gem-dimethyl group of the antibiotic (Figure 34 B) . [161] Based on these structure-based findings,medicinal chemists tried to install the siderophore moiety at amore beneficial position. [161] [162] [163] Compound 50 ( Figure 33 , discovered at AstraZeneca) represents am ost recent successful example of such as tructure-based approach that allows the design of siderophore-conjugated monocarbams with optimized binding interactions to P. aeruginosa PBP3 (Figure 34 C) . [163] Besides reinstalling the strong interaction of the drug molecule with Arg489, it positions the polar siderophore in am ore hydrophilic environment and allows the drug to make additional interactions with the target protein PBP3 (Figure 34 C) . Compound 50 features excellent pharmacokinetic properties and strong cellular activity against P. aeruginosa (P. aeruginosa ARC545;MIC = 0.5 mgmL À1 ).
[163] 
b-Lactamase Inhibitors
As discussed previously, b-lactam antibiotics are one of the oldest and most used classes of antibiotics.R esistance to these antibacterial agents predominantly occurs through the production of two different types of molecules: b-lactamases and b-lactam-resistant PBPs. b-Lactamases have been classified according to two schemes:t he Ambler and the BushJacoby classification. [164, 165] Thef irst b-lactamase inhibitor to be used was clavulanic acid (51,discovered at Beecham Pharmaceuticals) in the mid1970s, [166] followed over the next decade by sulbactam (52) [167] and tazobactam (53) . [168] As seen in Figure 35 , these blactamase inhibitors all possess a b-lactam core,but they have been shown to have only limited antibiotic activity.T heir mode of action involves irreversible binding to b-lactamases, which prevents inactivation of the antibiotic (Figure 36 ). [169] Unfortunately these three b-lactamase inhibitors are only effective against one of the four classes of b-lactamases,a nd the number of naturally occurring b-lactamases has risen exponentially over the last 20 years since the introduction of tazobactam. Novel b-lactamase inhibitors with extended spectra are now greatly needed. New b-lactamase inhibitors that are based on structural design and do not contain a blactam structure are currently being investigated.
Diazabicyclooctanes
Thef irst class of these "non-b-lactam inhibitors" are the diazabicyclooctanes (DBOs), which were first proposed in the mid-1990s (Hoechst Marion Roussel). [170, 171] These inhibitors are more potent and have abroader spectrum than current blactamase inhibitors.M echanistically,t hey act in as imilar manner to the traditional b-lactam inhibitors,w ith the carbonyl group of the cyclic 5-membered urea (imidazolidin-2-one) serving as the electrophile for the active-site serine of the b-lactamase.T his structural similarity to b-lactams is highly important for rapid recognition by the b-lactamase (Figure 37 ). Unlike the traditional b-lactam inhibitors however,t hey are not subject to hydrolysis after acylation, but instead deacylate very slowly.T wo of these novel DBOs will be discussed here.
Avibactam
Avibactam (54;p reviously NXL-104, AV E1330A, developed by Actavis) is aDBO that was approved by the FDAin 2015 in combination with the b-lactam ceftazidime (46) and is still in clinical studies in combination with ceftaroline (43)and aztreonam (49) . [172] It is ac ovalent, reversible inhibitor that has been shown to have avery fast "on" rate,aswell as avery slow "off" rate for deacylation, with ah alf-life measured in days. [173] X-ray crystal structures of avibactam in complex with three different b-lactamases have provided important insight into the mode of action. [174] [175] [176] Avibactam interacts with conserved key residues in afairly rigid conformation, and the highly polar sulfate group (which mimics the b-lactam carboxylic acid, Figure 37 ) engages in strong polar interactions with Arg261 ( Figure 38) . [177] Once covalently bound, avibactam remains in as imilar conformation, which, along with the stability of the newly formed carbamoyl bond and the additional favorable interactions,e xplains the deacylation pathway over hydrolysis.G iven the small size of avibactam and the efficient interactions with key catalytic residues near the active site,t his should allow binding to nearly all blactamases.T his could have positive implications for the suppression of emergence of new resistance in the clinic.
Relebactam
Relebactam (55;p reviously MK-7655, Merck and Company,F igure 37) is structurally very similar to avibactam, the only difference being the addition of apiperidine ring on the Angewandte Chemie Reviews amide.T he choice of this heterocycle came from screening avariety of basic and neutral heterocyclic side chains,taking into account results obtained with ap revious inhibitor MK-8712 (56) . [178] It was found that the addition of abasic nitrogen atom greatly helped to reduce efflux from the bacterial cell. [178] 
Boronic Acids
Boronic acids were already recognized as effective inhibitors of serine proteases in the 1970s. [179] Indeed, the boron atom can act as an electrophile,m imicking ac arbonyl carbon atom, which can lead to the formation of areversible covalent bond between the serine and the boronate moiety. Since Kiener and Waley described the use of phenylboronic acid as a b-lactamase inhibitor in 1978, anumber of research groups have looked into this functional group to generate novel inhibitors. [180] Surprisingly,i ti so nly very recently that the first boronate has been tested in an animal infection model. [181] 4.2.1. RPX7009 Ac yclic boronic acid b-lactamase inhibitor is currently under development (Rempex Pharmaceuticals,as ubsidiary of TheM edicines Company). Theo riginal inspiration for its design comes from areport published in 2000 by Ness and coworkers in which compound 57 is described. [182] This led to the idea of using cyclic boronates as inhibitors.W ith the boronic ester locked in ar ing, the inhibitor is constrained into ap referred conformation, thereby resulting in increased potency. Computational docking of several structures with different b-lactamase enzymes led to the discovery of the core structure shown in Figure 39 . From this first hit, al arge variety of compounds with varying N-acyl substituents were synthesized. The2-thienyl acetyl analogue RPX7009 (58)was found to be the most potent derivative,w hile also displaying ab road spectrum of inhibition and high selectivity. [181] RPX7009 is ab road-spectrum inhibitor,n otably restoring the activity of carbapenems against carbapenemase-producing K. pneumoniae strains.C ombined with ac arbapenem, RPX7009 is ap romising candidate for the treatment of multidrug resistant Gram-negative bacteria. [183] X-ray co-crystal structures of RPX7009 with b-lactamase enzymes confirmed the boron atom as the electrophilic site for the serine addition, as well as ah ydrogen-bonding network between both the amide and the carboxylic acid groups and the enzyme backbone ( Figure 40 ). This information could be used for further structure-based optimization of this novel chemotype of b-lactamase inhibitors.
Oxaboroles
Recently,t he design and synthesis of broad-spectrum boron-based b-lactamase inhibitors has been published (AstraZeneca). [184] Thea pproach taken is av ery nice and well described example of structure-based drug design that could potentially inspire future work in this field.
Verheijen et al. used two recent publications as starting points to come up with 2-(1-hydroxy-6-phenoxy-1,3-dihydrobenzo[c] [1, 2] oxaborol-3-yl)acetic acid (59)a sa ni nitial scaffold (Figure 41 ). [185, 186] An SAR study revealed the importance of the carboxylic acid and ether substituents. While the phenyloxy-substituted analogue showed slightly higher affinity against apanel of representative b-lactamases, the pyrazine analogues were synthetically less challenging and were therefore preferred for further optimization studies.
Docking studies against various b-lactamases revealed alipophilic pocket near C4 and C5. This pocket was found to be only able to accommodate small methyl groups,which led to the advancement of compound 60.A tt his stage,c hiral separation also revealed that the R-enantiomer was the most active.F inally the pyrazine ring was replaced with an umber of different heterocycles to try and increase the affinity for class A, C, and D b-lactamases.Eventually,compound 61 was found to have the highest overall affinity against various blactamases,with half maximal inhibitory concentration (IC 50 ) values in the nanomolar range.F or ceftazidime (46) , the application of 61 reduced the MIC in E. coli to 0.25 mgmL 
Intervention at the Genetic Level
Tr anscription factors are responsible for the regulation of gene transcription and are therefore essential in aw ide variety of cellular processes. [187] They contain specific DNAbinding domains with which they bind to specific DNA sequences and thereby regulate gene transcription. Interference at the genetic level by using small molecules that target the transcription factor binding sites enables control of gene expression. [188, 189] Since the ability of bacteria to develop antibiotic resistance is encoded in their genomes,t argeting the relevant transcription factors offers ac omplementary approach to fighting antibiotic resistance,i na ddition to the development of new antibiotic compounds.T his strategy benefits from recent genomic data as well as from detailed information about the molecular structure of transcription factors.
Several promising results were recently achieved by using either oligonucleotides (McArthur et al.,P rocarta Biosystems Ltd.) [190] or small drug-like compounds (Baulard et al., BioVersys AG,Riedl et al.) [191, 192] as interfering molecules.
Targeting the Transcription Factor EthR
Baulard et al. delivered an excellent example of how to target atranscription factor by structure-based design in order to positively influence the genetic machinery of ab acterium with respect to its susceptibility against ag iven antibiotic agent. [191] They targeted the transcriptional repressor EthR, am ember of the Te tR family of repressors, [193] which blocks the transcription of ethA.T his gene encodes the monooxygenase EthA, which catalyzes the activation of the prodrug ethionamide in Mycobacterium tuberculosis (Mtb). [194] Ethionamide is recommended by the WHO for the treatment of multidrug-resistant tuberculosis (MDR-TB), but it has alow therapeutic index. Since most of the adverse effects are dose-related, an increase in the bioactivation of ethionamide should reinforce its benefit for the treatment of MDR-TB.T he analysis of X-ray data for EthR bound to small-molecule ligands (PDB IDs:1 U9N,1 T56) [195, 196] suggested that holoprotein conformations are not able to bind DNA. Selective binders to EthR would therefore inhibit the repression of ethA expression. This should in turn boost the activation of ethionamide and thus reduce the amount of prodrug which needs to be administered. Thec hemical structure and binding orientation of the initial ligands identified in the co-crystal structures (PDB IDs:1 U9N, 1T56;F igure 42) inspired the fragment-based design and synthesis of af ocused library of drug-like small molecules.
Out of this library,t hey could identify the initial leads BDM14500 and BDM31343 (62 and 63;F igure 43). These compounds inhibit the DNA-binding function of EthR.
Further medicinal chemistry optimization by as tructurebased strategy led to compound 64 ( Figure 43) , which decreases the Mtb load of infected mice three times more effectively than ethionamide alone. [197] These boosters of ethionamide bioactivation are currently being developed toward preclinical testing. [198] Figure 41. Structure-activity relationships contributingtothe development of new boron-based b-lactamase inhibitors (60, 61) . Figure 42 . Overlay of the EthR crystal structure containing dioxane fragments (C purple;P DB ID:1T56) and the co-crystal structure of BDM14500 (62;Cgreen) bound to the transcription factor EthR (PDB ID:3 G1O), both from M. tuberculosis.
Targeting the Transcription Factor TetR
Thet ranscription factor Te tR has been successfully targeted with drug-like small molecules in order to treat tetracycline resistant Gram-positive and Gram-negative pathogens (Bioversys AG in collaboration with our group). These molecules,c alled transcription regulator inhibitory compounds (TRICs) target transcription factors that are responsible for the development of resistance. [192] Thea im is to use TRICs as adjuvants for restoring or potentiating the impact of antibiotics in order to overcome bacterial resistance. [198] Bacteria have developed extensive resistance mechanisms against tetracyclines,i ncluding tetracycline efflux, ribosomal protection, and tetracycline modification. [199] The two most dominant mechanisms in clinical settings are ribosomal protection and efflux. [199] Thel atter is mediated by the membrane transport protein Te tA. [200] Thee xpression of this protein is regulated by the Te trepressor (TetR), which binds to the DNAa nd prevents the transcription of tetA. [201] When tetracycline binds to Te tR with the aid of Mg 2+ (Figure 44 ), such as when it binds to its ribosomal target, the conformation of TetR changes and transcription of the resistance genes take place. [199, 201, 202] By following astructure-based approach based on the cocrystal structure of Te tR with tetracycline in combination with aDNA/Protein (tetO/TetR) interaction assay,i twas possible to design and develop compounds ZHAWOC1035 and ZHAWOC1132 (65 and 66;F igure 45), which specifically bind to Te tR and prevent its release from the DNAi nt he presence of tetracycline. [192] In combination with tetracycline, these drug-like small molecules were able to inhibit the growth of tetracycline-resistant staphylococcal, enterococcal, enterobacterial, and acinetobacter isolates. [192] 6. Summary and Outlook Thea larming spread of antibiotic resistance has been recognized by relevant institutions such as the World Health Organization. After decades of declining efforts by the pharmaceutical industry in their search and development of new antibiotic treatment options,t he latest wake-up calls have already brought some increase in activity in this exciting area of multidisciplinary research. Structural and mechanistic understanding of antibacterial targets and deciphering of the bacterial ability for developing antibiotic resistance provide as ound basis for rational campaigns against antibiotic resistance.Screening for new natural or synthetic compounds with antibiotic effects based on novel antibacterial targets still provide one route to outstanding discoveries in the field [203] but structural knowledge enables us to work directly on the resistance mechanisms with increasing success,a sshown by some selected examples in this review.Amultipronged strategy that involves targeting traditional and emerging antibiotic targets as well as pursuing adjuvant strategies at the genetic level with non-antibiotic compounds for potentiating known antibiotics gives rise to many opportunities to overcome antibiotic resistance.Beyond the basic considerations of the pharmaceutical industry concerning return on investments for the discovery and marketing of new antibiotic treatments,there is the invaluable power of antibiotics,which has helped to save am yriad of lives in the past and which nobody would like to see disappear.S ince the level of resources required and the associated costs for developing anew drug molecule are very high and the expected financial gains from antibiotic treatments,w hich are typically only required for short periods,a re relatively low compared to treatments for chronic conditions,t he willingness for industrial players to start substantial efforts to discover new antibiotic treatment options remains low.N evertheless, pharmaceutical companies are needed as strong partners in drug development programs,g iven their experience and knowledge of the highly complex endeavor of bringing an ew drug molecule to the clinic. It is not sufficient to have acompound that kills bacteria on apetri dish. It takes alot of complex medicinal chemistry optimization in order to be able to use the compound to treat bacterial infections in humans. Whereas the strength and mandate of academic institutions is Angewandte Chemie Reviews to develop novel strategies for ensuring antibiotic treatment options for the future,t he final processing of new antibiotic drug molecules and their development through clinical studies is the domain of the pharmaceutical industry.A reasonable approach for integrating these two aspects is acloser interaction between industrial and academic partners in drug discovery for the mutual benefit of both partners and the patients.T here are several examples in which major pharmaceutical companies have "opened their doors" and started cooperating very early on with academic groups on drug discovery projects.T hese "open innovation" collaborations provide easy reciprocal access to resources that the partners would not have otherwise.O ne characteristic of those open innovation approaches is that they are not focused on as pecific drug development program from the beginning but rather screen the best scientific ideas and strategies for new therapeutic indications,i ncluding antibiotic resistance. More focused collaborations can then be defined later by research consortia between academic partners,biotechnology companies,a nd large pharmaceutical companies in order to develop clinical drug candidates.These translational research approaches and public-private initiatives such as the Innovative Medicines Initiative (IMI) can help to overcome the gap between basic research and am arketed drug. In particular, research into new strategies against antibiotic resistance should benefit from this new drug discovery concept, given the relevance of this challenge for public health.
